# TAMARACK (NCT05551117)

> A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

No report yet. It can be ordered.

- Drugs tested: vobramitamab duocarmazine
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05551117
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: MacroGenics
- Conditions: Castration-Resistant Prostatic Cancer; Androgen-Independent Prostatic Cancer; Androgen-Insensitive Prostatic Cancer; Androgen-Resistant Prostatic Cancer; Hormone Refractory Prostatic Cancer; Anal Cancer; Anal Neoplasm; Carcinoma, Squamous Cell of Head and Neck; Head and Neck Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oral Squamous Cell Carcinoma; Malignant Melanoma; Melanoma; Non-small Cell Lung Cancer; Non-small Cell Carcinoma; Small-cell Lung Cancer; Small Cell Carcinoma
- Interventions: vobramitamab duocarmazine 2.0 mg (Arm A); vobramitamab duocarmazine 2.7 mg (Arm B); vobramitamab duocarmazine; Abiraterone; Enzalutamide
- Enrollment: 192
- Primary outcome: Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator
- Primary outcome: Part 2: Objective Response Rate (ORR) Per Investigator Assessment of Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Criteria

## Indexed commentary on TAMARACK so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=tamarack-nct05551117